Taiwanese start-up Molsentech, ultra-high sensitivity biomedical detection technology, launches on the world stage


TAIPEI, July 28, 2022 /PRNewswire/ — Thanks to its impressive achievements, Molsentech (Molecular Sensoring Technology Co., Ltd.) has been selected for the TTA Global Challenge sponsored by Taiwan The Department of Science and Technology will attend US BIO 2022, ready to leverage its US market introduction as a springboard to leap further onto the global stage. The company has successfully launched an electrical detection system using ultra-high sensitivity biomedical detection technology that can be applied to the detection of various early-stage diseases, including SARS-CoV-2.

Founded in Taiwan, the world’s leading semiconductor center, Molsentech’s breakthrough was the development of a 100% semiconductor biosensor platform that offers valuable healthcare application for disease detection. The core technology is called Bio-FET which allows biosensors to analyze samples in liquid form by measuring electrical signal changes caused by interactions between sensing targets and modified bioprobes on the surface of the biosensors. Patented in United States, Taiwanand Chinathe technology overcomes one of the biggest challenges in the industry when dealing with samples in liquid form, interpreting samples in 5 minutes to provide immediate results.

Molsentech’s bio-FET technology remains new to the biotech industry; therefore, in the beginning, it mainly played a supporting role for common detection techniques, validating the detection results provided by tests such as PCR and ELISA with its ultra-high sensitivity. During the COVID-19 pandemic, the Molsentech SARS-CoV-2 test chip was granted Emergency Use Authorization (EUA) by the Food and Drug Administration for use in the manufacture of new SARS-CoV-2 test kits. CoV-2 that have resulted in faster testing process and greater accuracy. This demonstrates the ability of bio-FET technology to function independently as a biotechnology for molecular diagnostics. Therefore, greater cooperation is being negotiated between Molsentech and other leading biotech companies, including, but not limited to, Taiwanbased

As its technology is now available for commercial use globally, Molsentech intends to further expand its global market presence, initially in United States, a country with the most advanced healthcare ecosystem to take its technology and products to the next level. “Fortunately, we were lucky enough to establish our footprint in United States, this would pave the way for Molsentech to move forward. We will definitely take this opportunity to showcase how our technology can help more people,” said Dr. Chia Jun ChuCEO of Molsentech.

The company achieved a turnover of 1 million TWD and conducted more fundraising activities in Taiwan and United States.

About Molsentech

Established in Taiwan in 2014, Molsentech’s mission is to invent an innovative biomedical platform that allows non-invasive and real-time detection of a minimum of pathogens. The core team includes leading experts from Academia Sinica’s Quantum Electronics Laboratory who have unique skills and experience in the semiconductor industry, particularly in chip design/fabrication, modification of probe molecules and the integration of automated biosensor systems. Thanks to its continuous efforts and commitment to high product quality and innovation, the company has been recognized with various prestigious awards and accolades.

SOURCE Molecular Detection Technology


About Author

Comments are closed.